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LETTER TO THE EDITOR: REPLY TO PUBLISHED MANUSCRIPT
Recurrences of Scleritis after Ocular Surgery
D.P.C. Vergouwen , MDa,b, J.C. Ten Berge , MD PhDa, and A. Rothova , MD PhDa
aDepartments of Ophthalmology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands; bImmunology, Erasmus MC, 
University Medical Centre Rotterdam, Rotterdam, The Netherlands
Editor,
In the May 2020 issue of Ocular Immunology and 
Inflammation, an interesting study by Palkar et al. entitled 
‘Cataract surgery in the setting of scleritis’ was published, 
which reported on surgical management of patients 
with previous scleritis.1 The authors concluded that con-
trol of inflammation activity prior to cataract surgery was 
essential for successful outcome.1 Though surgery is com-
monly needed for the complications of scleritis such 
as cataract and glaucoma, the publications on this topic 
are scarce.2
It is known that ocular surgery in patients with (prior) 
scleritis can lead to severe complications and permanent visual 
loss.3 Previously recognized risk factors for recurrence of scler-
itis after ocular surgery included the presence of systemic 
immune-mediated diseases, a short time of remission before 
surgery, multiple surgeries, and use of corneoscleral incision in 
cataract surgery.3–5
This has led to the recommendation of diverse expert opi-
nion-based preventive measures for intraocular surgery in 
scleritis patients; however, clear guidelines are lacking.6 In 
this study, we confirm the main conclusions of the study of 
Palkar et al. and wish to add novel data on recurrences of 
scleritis after cataract as well as glaucoma surgery in patients 
with previous non-infectious scleritis from our institution.
We conducted a retrospective cohort study, wherein we 
reviewed 103 patients with scleritis from the Erasmus Medical 
Center (Rotterdam, The Netherlands). We included all 16 patients 
with noninfectious scleritis, who had undergone ocular surgery 
after the onset of their scleritis, between 2005 and 2019. An 
additional 10 patients developed scleritis de novo after surgery 
but were not included in our present series. This study has 
followed the Tenets of the Declaration of Helsinki and was per-
formed with the permission of the local Medical Ethics 
Committee.
We registered baseline characteristics, time in remission 
before surgery, type of surgery, ongoing systemic treat-
ment, and use of additional perioperative systemic corti-
costeroids. The main outcome was recurrence of scleritis 
within 3 months after surgery. Continuous data were 
reported as median and range, and categorical data as 
number and percentage. Mann–Whitney U-test and 
Fisher’s exact test were used to analyze results, while a p 
value less than 0.05 was considered significant.
The included 16 patients had undergone a total of 24 
ocular surgeries (Table 1). The median age at onset of 
scleritis was 60 years (range 45–81) and 9/16 patients 
(56%) were male. Bilateral disease occurred in 10/16 
patients (63%), 5/16 (31%) had anterior scleritis, and 4/16 
(25%) had scleral necrosis. Systemic immune-mediated dis-
eases were diagnosed in 10/16 (63%) patients, whereof 30% 
had granulomatosis with polyangiitis, 20% rheumatoid 
arthritis, and 50% other disorders. A biological agent was 
required in 8/16 (50%), mainly rituximab (6 patients; 2 had 
adalimumab and one tocilizumab). Average follow-up was 
75 months (range 11–181).
Recurrence of scleritis within 3 months after surgery 
occurred in 4/24 surgeries (4/24; 17% of surgeries; 4/16; 
25% of patients; Table 1). All four patients with recurrences 
had a systemic disease and were younger than the patients 
without the remissions. In surgeries followed by recurrences, 
the time of inactive scleritis prior to surgery was shorter (all 
shorter than 6 months; Table 1). A corneoscleral incision 
was used in all three cataract extractions followed by recur-
rences. Use of ongoing systemic treatment and administra-
tion of perioperative systemic corticosteroids did not differ 
between patients with and without recurrences.
Surprisingly, recommended preventive measures were 
not used in a large percentage of patients with previous 
scleritis. This is in accordance with the article of Palkar 
et al., and this phenomenon might reflect a lack of clear 
guidelines or a lack of knowledge of importance of these 
precautions. Our study is limited by a small number of 
patients, its retrospective character, and probable bias 
toward severe scleritis in a tertiary center. A more extended 
study would be required for the evaluation of specific pre-
ventive measures.
In conclusion, we confirm that ocular surgery can be 
performed reasonably safely in patients with prior scleritis, 
and point out that the duration of remission before sur-
gery is crucial. Our limited data show that a period of 
several months of inactive scleritis before surgery is 
desirable.
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Table 1. Characteristics and recurrences of scleritis after intraocular surgery in 













Type of ocular surgery: 
cataract extraction
18/24 (75%)c 15/20 (75%) 3/4 (75%) -
Average time in 
remission before 
surgery in months 
(range)
14.4 (0–86) 17.0 (0–86) 2.2 (1–5) 0.02
Time in remission before 
surgery for at least 
6 months




18/24 (75%) 14/20 (70%) 4/4 (100%) 0.54
Addition of perioperative 
systemic 
corticosteroids
15/24 (63%) 12/20 (60%) 3/4 (75%) 1.00
Corneal incision 7/15d (47%) 7/12 (58%) 0/3 (0%) 0.20
aFour surgeries involved four patients. 
bTwo additional patients had temporary post-surgical macular edema, but their 
scleritis remained quiet. 
cThe remaining surgeries included two pterygium excisions, two vitrectomies, one 
trabeculectomy, and one Ahmed implant. Recurrence occurred after the Ahmed 
implant. 
dIn cases with cataract extraction; details about the incision were unknown in 
three cases.
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